Thromboembolism Clinical Trial
Official title:
Evaluation of ReX-C System in Measurement and Improvement of Adherence, in Patients Receiving Oral Anti-coagulation Therapy for the Treatment and Prevention of Thromboembolism.
The study aims to evaluate the safety, usability and efficacy of the ReX-C - a novel medication management system - in measurement and improvement of adherence, in patients receiving oral anti-coagulation therapy for the treatment and prevention of thromboembolism.
ReX-C is a mobile system intended to provide solid, oral medication on patient demand, according to a pre-programmed treatment protocol. ReX-C addresses poor adherence to medication therapy by providing real-time, reliable adherence data to caregivers and timely, personalized reminders to patients. During the study, the use of ReX-C system to receive medications will be compared to Standard of Care. Patients' adherence will be evaluated for both methods. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Enrolling by invitation |
NCT05794165 -
Antithrombin to Improve Thromboprophylaxis and Reduce the Incidence of Trauma-Related Venous Thromboembolism
|
Phase 2 | |
| Active, not recruiting |
NCT05563883 -
Atrial Fibrillation and Cancer: a Nationwide French Cohort Study
|
||
| Terminated |
NCT02475187 -
Observational Study of Thrombogenic Properties in 220 Patients With Proximal Femur Fracture
|
||
| Recruiting |
NCT00982514 -
Thromboembolic Complications Related to Asparaginase in Children With Acute Lymphoblastic Leukemia (ALL) Treated According to NOPHO ALL 2008
|
N/A | |
| Completed |
NCT01420809 -
Special Drug Use Investigation for ARIXTRA® (Fondaparinux) Injection
|
N/A | |
| Terminated |
NCT00206089 -
Melagatran/Ximelagatran Versus Enoxaparin for the Prevention of Venous Thromboembolic Events
|
Phase 3 | |
| Completed |
NCT00014352 -
Combination Chemotherapy Plus Warfarin in Treating Patients With Prostate Cancer
|
Phase 2 | |
| Completed |
NCT00000614 -
Prevention of Recurrent Venous Thromboembolism (PREVENT)
|
Phase 3 | |
| Active, not recruiting |
NCT05656963 -
The Influencing Factors and Mechanism of High Incidence of Thrombotic Events in Patients With MN and DKD
|
||
| Completed |
NCT04719182 -
Practice of Adjunctive Treatments in Intensive Care Unit Patients With COVID-19
|
||
| Completed |
NCT02935751 -
Apixaban Discontinuation Prior to Major Surgery
|
||
| Terminated |
NCT02579122 -
REVIparin-BRIDging-in a General Practice Setting in GErmany
|
||
| Completed |
NCT01696760 -
Aspirin and Compression Devices for VTE Prophylaxis in Orthopaedic Oncology
|
N/A | |
| Completed |
NCT00986154 -
Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).
|
Phase 3 | |
| Terminated |
NCT00662688 -
Chemotherapy With or Without Dalteparin in Treating Patients With Metastatic Pancreatic Cancer
|
Phase 3 | |
| Completed |
NCT00260988 -
A Comparison of Dalteparin and Tinzaparin for Prevention of Blood Clots in Hemodialysis Patients on Oral Anticoagulants Having Surgery
|
Phase 2/Phase 3 | |
| Terminated |
NCT00031837 -
Gemcitabine With or Without Dalteparin in Treating Patients With Unresectable or Metastatic Pancreatic Cancer
|
Phase 3 | |
| Completed |
NCT03877770 -
DVT After Cardiac Procedure
|
||
| Completed |
NCT00024297 -
Warfarin in Preventing Blood Clots in Cancer Patients With Central Venous Catheters
|
N/A | |
| Recruiting |
NCT06118957 -
Low Molecular Weight Heparin or no Treatment Following Cesarean Delivery
|
Phase 2 |